Design, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivatives
 
Yazarlar (7)
Doç. Dr. Feyzi Sinan TOKALI Kafkas Üniversitesi, Türkiye
Doç. Dr. Parham Taslimi Bartin Üniversitesi, Türkiye
İbrahim H. Demircioğlu
Atatürk Üniversitesi, Türkiye
Doç. Dr. Muhammet Karaman Kilis 7 Aralik Üniversitesi, Türkiye
Mehmet S. Gültekin
Atatürk Üniversitesi, Türkiye
Kıvılcım Şendil
Kafkas Üniversitesi, Türkiye
İlhami Gülçin Atatürk Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Archiv Der Pharmazie (Q3)
Dergi ISSN 0365-6233 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 05-2021
Cilt / Sayı / Sayfa 354 / 5 / 2000455–0 DOI 10.1002/ardp.202000455
Makale Linki https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202000455
UAK Araştırma Alanları
Organik Kimya
Özet
3‐Amino‐2‐ethylquinazolin‐4(3H)‐one (3) was synthesized in two steps from the reaction of amide (2), which was obtained from the treatment of methyl anthranilate (1) with propionyl chloride, with hydrazine. From the reaction of 3‐amino‐2‐ethylquinazolin‐4(3H)‐one (3) with various aromatic aldehydes, novel benzylidenaminoquinazolin‐4(3H)‐one (3a–n) derivatives were synthesized. The structures of the novel molecules were characterized using infrared spectroscopy, nuclear magnetic resonance spectroscopy (1H‐NMR and 13C‐NMR), and high‐resolution mass spectroscopy. The novel compounds were tested against some metabolic enzymes, including α‐glucosidase (α‐Glu), acetylcholinesterase (AChE), and human carbonic anhydrases I and II (hCA I and II). The novel compounds showed Ki values in the range of 244–988 nM for hCA I, 194–900 nM for hCA II, 30–156 nM for AChE, and 215–625 …
Anahtar Kelimeler
3-aminoquinazolin-4(3H)-one | enzyme inhibition | metabolic enzymes | molecular docking | Schiff bases
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Web of Science 40
Scopus 38
Google Scholar 40
Design, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivatives

Paylaş